Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14787210.2021.1848545 http://scihub22266oqcxt.onion/10.1080/14787210.2021.1848545 33187459!ä!33187459 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Rev+Anti+Infect+Ther 2021 ; 19 (6): 679-687 Nephropedia Template TP {{tp|p=33187459|t=2021. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review |pdf=|usr=}}{{33187459}} gab.com Text Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review JO: Expert Rev Anti Infect Ther http://www.kidney.de/pget.php?&tw=1&pmid=33187459 #FOAvip Objectives: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with Cornonavirus disease 19 (COVID-19) to assess the efficacy of LPV/r for the treatment of COVID-19.Methods: The authors systematically searched PubMed and MedRxiv databases for studies describing treatment of COVID-19 patients using LPV/r compared to other therapies. Articles were excluded if they were case reports, opinion editorials, preclinical studies, single-armed studies, not written in English, not relevant to the topic, or published before May 2020. The included outcomes were viral clearance as measured by reverse-transcription polymerase chain reaction (RT-PCR) negativity and/or improvement on chest computed tomography (CT), mortality, and adverse events.Results: Among 858 total studies, 16 studies met the inclusion criteria and were included in the qualitative review. These studies consisted of 3 randomized control trials, 3 open-label trials, and 10 observational studies. Most of these studies did not report positive clinical outcomes with LPV/r treatment.Conclusion: The systematic review revealed insufficient evidence of effectiveness and clinical benefit of LPV/r in the treatment of COVID-19 patients. Specifically, LPV/r does not appear to improve clinical outcome, mortality, time to RT-PCR negativity, or chest CT clearance in patients with COVID-19. Twit Text FOAVip Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review ????Expert Rev Anti Infect Ther http://www.kidney.de/pget.php?&tw=1&pmid=33187459 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33187459 #FOAvip English Wikipedia <ref>{{Cite pmid|33187459}}</ref> Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review #MMPMID33187459 Joseph BA; Dibas M; Evanson KW; Paranjape G; Vegivinti CTR; Selvan PT; Saravu K; Gupta N; Pulakurthi YS; Keesari PR; Varsha S; Chittajallu S; Dmytriw AA; Reierson NL; Mikoff N; Kamrowski S; Schmidt M; Davis AR; Pederson JM; Mishra HK; Touchette JC; Kallmes K Expert Rev Anti Infect Ther 2021[Jun]; 19 (6): 679-687 PMID33187459show ga Objectives: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with Cornonavirus disease 19 (COVID-19) to assess the efficacy of LPV/r for the treatment of COVID-19.Methods: The authors systematically searched PubMed and MedRxiv databases for studies describing treatment of COVID-19 patients using LPV/r compared to other therapies. Articles were excluded if they were case reports, opinion editorials, preclinical studies, single-armed studies, not written in English, not relevant to the topic, or published before May 2020. The included outcomes were viral clearance as measured by reverse-transcription polymerase chain reaction (RT-PCR) negativity and/or improvement on chest computed tomography (CT), mortality, and adverse events.Results: Among 858 total studies, 16 studies met the inclusion criteria and were included in the qualitative review. These studies consisted of 3 randomized control trials, 3 open-label trials, and 10 observational studies. Most of these studies did not report positive clinical outcomes with LPV/r treatment.Conclusion: The systematic review revealed insufficient evidence of effectiveness and clinical benefit of LPV/r in the treatment of COVID-19 patients. Specifically, LPV/r does not appear to improve clinical outcome, mortality, time to RT-PCR negativity, or chest CT clearance in patients with COVID-19. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/administration & dosage/*therapeutic use[MESH] |Drug Combinations[MESH] |Humans[MESH] |Lopinavir/administration & dosage/adverse effects/*therapeutic use[MESH] |Ritonavir/administration & dosage/adverse effects/*therapeutic use[MESH] |SARS-CoV-2/*drug effects[MESH]Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-1(epmc).pdf DeepDyve Pubget Overpricing